On 6 September 2017, the Sun emitted two significant solar flares (SFs). The first SF, classified X2.2, peaked at 09:10 UT. The second one, X9.3, which is the most intensive SF in the current solar cycle, peaked at 12:02 UT and was accompanied by solar radio emission. In this work, we study ionospheric response to the two X-class SFs and their impact on the Global Navigation Satellite Systems and high-frequency (HF) propagation. In the ionospheric absolute vertical total electron content (TEC), the X2.2 SF caused an overall increase of 2-4 TECU on the dayside. The X9.3 SF produced a sudden increase of ~8-10 TECU at midlatitudes and of ~15-16 TECU enhancement at low latitudes. These vertical TEC enhancements lasted longer than the duration of the EUV emission. In TEC variations within 2-20 min range, the two SFs provoked sudden increases of ~0.2 TECU and 1.3 TECU. Variations in TEC from geostationary and GPS/GLONASS satellites show similar results with TEC derivative of ~1.3-1.7 TECU/min for X9.3 and 0.18-0.24 TECU/min for X2.2 in the subsolar region. Further, analysis of the impact of the two SFs on the Global Navigation Satellite Systems-based navigation showed that the SF did not cause losses-of-lock in the GPS, GLONASS, or Galileo systems, while the positioning error increased by ~3 times in GPS precise point positioning solution. The two X-class SFs had an impact on HF radio wave propagation causing blackouts at <30 MHz in the subsolar region and <15 MHz in the postmidday sector.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473633 | PMC |
http://dx.doi.org/10.1029/2018SW001932 | DOI Listing |
Breast
January 2025
Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China; Shanghai Key Laboratory of Proton Therapy, Shanghai, 201801, China. Electronic address:
Purpose: This study aims to assess whether dual anti-HER2 therapy with trastuzumab and pertuzumab increases early cardiac toxicity compared to trastuzumab alone in breast cancer (BC) patients receiving postoperative radiation therapy (RT).
Methods: Consecutive operable BC patients receiving postoperative RT and trastuzumab with or without pertuzumab between January 2017 and September 2020 at seven tertiary hospitals in China were retrospectively reviewed. Cardiac examinations included echocardiography, electrocardiogram (ECG), NT-proBNP, and cTnI at baseline before RT and during the follow-up.
Cancers (Basel)
December 2024
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita 5650871, Japan.
Background: FOLFIRI (5-FU + leucovorin + irinotecan) plus ramucirumab is one of the standards in second-line metastatic colorectal cancer (CRC) patients progressing after treatment with oxaliplatin/fluoropyrimidine with bevacizumab, but there is no evidence on its efficacy without prior bevacizumab. Moreover, VEGF-D has not been confirmed as a predictive biomarker for ramucirumab's efficacy, either.
Methods: The RAINCLOUD study was a multicenter, single-arm, phase II trial conducted in Japan.
Animals (Basel)
December 2024
Instituto de Investigaciones Sobre los Recursos Naturales, Universidad Michoacana de San Nicolás de Hidalgo, Morelia 58330, Michoacán, Mexico.
J Cancer Res Ther
December 2024
Department of Interventional Radiology, Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China.
Objective: To evaluate the postoperative complications and prognosis of renal cell carcinoma (RCC) in a solitary kidney after irreversible electroporation (IRE).
Materials And Methods: A total of 8 patients with 9 RCCs in a solitary kidney treated with computed tomography (CT)-guided IRE from February 2017 to September 2020 were retrospectively analyzed. Follow-up included contrast-enhanced CT or magnetic resonance imaging examinations at 1 day, 1 week, 1 month, 3 months, 6 months, 12 months, and each year after IRE and the evaluation of the incidence of postoperative complications, renal function changes, local tumor recurrence, and metastasis.
JAMA Netw Open
January 2025
University Centre for Rural Health, School of Health Sciences, University of Sydney, Lismore, New South Wales, Australia.
Importance: An unhealthy lifestyle is believed to increase the development and persistence of low back pain, but there is uncertainty about whether integrating support for lifestyle risks in low back pain management improves patients' outcomes.
Objective: To assess the effectiveness of the Healthy Lifestyle Program (HeLP) compared with guideline-based care for low back pain disability.
Design, Setting, And Participants: This superiority, assessor-blinded randomized clinical trial was conducted in Australia from September 8, 2017, to December 30, 2020, among 346 participants who had activity-limiting chronic low back pain and at least 1 lifestyle risk (overweight, poor diet, physical inactivity, and/or smoking), referred from hospital, general practice, and community settings.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!